Osteogenesis Imperfecta Clinical Trial
Official title:
Non-invasive Blood Pressuring Monitoring in Patients With Osteogenesis Imperfecta: Does Circumferential Cuff Pressure Result in Fractures?
Osteogenesis Imperfecta (OI) is a genetic disorder caused by mutations to the alpha-1 or alpha-2 chain of type I collagen. Clinically, the disorder is characterized by bones that fracture easily, often from little or no apparent trauma. There is no information about Some institutions perform blood pressure monitoring on these patients with a cuff, while other institutions avoid this method due to concern for fracture. Instead, they use alternative forms of monitoring such as an arterial line. These methods come with their own risks, including clotting, decreased perfusion, and pain. In addition, arterial lines require intensive (and more expensive) monitoring in a pediatric intensive care unit due to risk of dislodgement and rapid blood loss. These blood pressure monitoring recommendations for patients with OI do not appear to be based on strong evidence. Anecdotally, some patients and healthcare professionals report hearing about individuals with OI who have suffered fractures from blood pressure cuffs. However, this is not well documented in the medical literature. Regular and accurate blood pressure monitoring is particularly important in the postoperative period, due to blood loss and fluid shifts, as well as utilization of advanced pain management techniques that can potentially impact blood pressure.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | December 31, 2024 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 1 Year to 35 Years |
Eligibility | Inclusion Criteria: - Patients with OI who are undergoing extremity surgery or spinal fusion surgery. - Patients between the ages of 1 and 35 years with OI who are admitted at our institution to a non-ICU inpatient setting in the postoperative period following an orthopedic surgery. - Patients who initially require ICU-level care but transition to a non-ICU setting following an orthopedic surgery. - Recent fracture in contralateral upper extremity (< 8 weeks, or upper extremity fracture that is not yet completely healed). - Must be able to tolerate upper extremity blood pressures. - Medical clearance by OI physicians (Kruse, Franzone) after review of fracture history, surgical procedures, x-rays. Exclusion Criteria: - Parent or child refusal, uncooperative child. - History of frequent upper extremity fracture on ipsilateral side, or recent upper extremity fracture on ipsilateral side if only that side may be used. - Clinical presence of thrombocytopenia (excessive or easy bleeding or bruising), admission or transfer to PICU. |
Country | Name | City | State |
---|---|---|---|
United States | Nemours / A I duPont Hospital for Children | Wilmington | Delaware |
Lead Sponsor | Collaborator |
---|---|
Nemours Children's Clinic |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Sphygmomanometer blood pressures | Cuff blood pressure measurements obtained without injury to patient with Osteogenesis Imperfecta | Every 4 hours for first 24 hours, then every 8 hours until discharge |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03557567 -
NGS Strategy Effectiveness in Molecular Diagnosis
|
||
Not yet recruiting |
NCT05559801 -
Mesenchymal Cell Therapy in Osteogenesis Imperfecta (OI)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02531087 -
Urinary Biomarkers of OI Pathobiology
|
||
Completed |
NCT01713231 -
Effect of High-Dose Vitamin D on Bone Density in Osteogenesis Imperfecta
|
Phase 4 | |
Completed |
NCT00655681 -
Prevention of Post Operative Bone Loss in Children
|
N/A | |
Recruiting |
NCT06065111 -
Study of Osteogenesis Imperfecta Tendon
|
||
Withdrawn |
NCT03216486 -
An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta
|
Phase 2 | |
Recruiting |
NCT06086613 -
A First-in-Human Study Evaluating AGA2115 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04009733 -
Epigenetic Regulation of Osteogenesis Imperfecta Severity : miROI Study
|
N/A | |
Completed |
NCT04231916 -
High Resolution Thermal Imaging to Identify Vertebral Fractures in Children and Young People With Osteogenesis Imperfecta
|
N/A | |
Active, not recruiting |
NCT02814591 -
Development of a Non-invasive Assessment of Human Bone Quality Using Spatially Offset Raman Spectroscopy
|
||
Completed |
NCT00982124 -
An Efficacy and Safety Trial of Intravenous Zoledronic Acid in Infants Less Than One Year of Age, With Severe Osteogenesis Imperfecta
|
Phase 3 | |
Completed |
NCT00001305 -
Growth Hormone Therapy in Osteogenesis Imperfecta
|
Phase 3 | |
Completed |
NCT04119388 -
Evaluation of the Benefits of Adaptive Physical Activity in Children and Adolescents With Osteogenesis Imperfecta
|
N/A | |
Terminated |
NCT01679080 -
The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta
|
Phase 2 | |
Completed |
NCT00106028 -
Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children
|
Phase 3 | |
Recruiting |
NCT04152551 -
Effects of Bisphosphonates on OI-Related Hearing Loss
|
Phase 4 | |
Completed |
NCT00705120 -
Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation
|
Phase 1 | |
Completed |
NCT03064074 -
Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta
|
Phase 1 | |
Not yet recruiting |
NCT05258019 -
Site Preservation After Tooth Extraction
|